Abbott’s MitraClip Device Receives FDA’s Expanded Indication Approval for Secondary Mitral Regurgitation (MR)

 Abbott’s MitraClip Device Receives FDA’s Expanded Indication Approval for Secondary Mitral Regurgitation (MR)

Abbott’s MitraClip Device Receives FDA’s Expanded Indication Approval for Secondary Mitral Regurgitation (MR)

Shots:

  • The approval is based on COAPT study assessing MitraClip + medical therapy vs medical therapy as monothx. in 614 patients with moderate to severe secondary MR across 78sites including the US & Canada
  • The COAPT study resulted in meting its 1EPs & 10 2EPs with the reduction in hospitalization & mortality 47% & 38% respectively
  • Abbott’s MitraClip is a novel transcatheter clip-based mitral valve intervention therapy & has received FDA’s approval in 2013 for reducing mitral regurgitation

Click here to read full press release/ article | Ref: Abbott | Image: Fortune

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post